Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study

Table 4 Multiple linear regression analysis for ln [TRACP-5b/iPTH]

Variable	Model 1	Model 2	Model 3	Model 4
Age, years		0.006 [−0.008, 0.021]	0.004 [−0.011, 0.019]	0.007 [− 0.009, 0.023]
Female sex		0.204 [−0.086, 0.494]	0.186 [−0.107, 0.478]	0.190 [− 0.103, 0.484]
BMI, kg/m²			−0.019 [− 0.057, 0.019]	−0.020 [− 0.057, 0.018]
Alb, g/dL				0.219 [−0.321, 0.759]
CaSR agonist use
None	(base)	(base)	(base)	(base)
Cinacalcet/ Evocalcet	−0.329* [− 0.642, − 0.015]	−0.313 [− 0.630, 0.004]	−0.296 [− 0.623, 0.030]	−0.284 [− 0.612, 0.045]
Etelcalcetide (i.v.)	−1.029** [−1.716, − 0.342]	−0.932** [− 1.629, − 0.236]	−0.940** [− 1.639, − 0.240]	−0.886* [− 1.599, − 0.173]
VDRA use
None	(base)	(base)	(base)	(base)
Alfacalcidol/ Falecalcitriol	−0.349 [− 0.926, 0.236]	−0.344 [− 0.927, 0.239]	−0.299 [− 0.888, 0.290]	−0.305 [− 0.895, 0.285]
Calcitriol (i.v.)	− 0.770** [− 1.340, − 0.200]	−0.815** [− 1.389, − 0.240]	−0.772* [− 1.353, − 0.191]	−0.791** [− 1.374, − 0.207]
Maxacalcitol (i.v.)	−0.749* [− 1.385, − 0.113]	−0.791* [− 1.434, − 0.148]	−0.810* [− 1.456, − 0.164]	−0.831* [− 1.481, − 0.182]
cCa, mg/dL	0.171 [− 0.057, 0.399]	0.117 [− 0.057, 0.398]	0.177 [− 0.051, 0.406]	0.209 [− 0.033, 0.451]
P, mg/dL	−0.123 [− 0.264, 0.017]	−0.113 [− 0.257, 0.029]	−0.095 [− 0.245, 0.054]	−0.097 [− 0.247, 0.053]
ln [1, 25(OH)₂D]	− 0.156 [− 0.470, 0.158]	−0.207 [− 0.528, 0.113]	−0.207 [− 0.529, 0.115]	−0.213 [− 0.535, 0.110]

Abbreviations: Alb Serum albumin, BMI Body mass index, CaSR Calcium-sensing receptor, cCa Corrected Ca, iPTH Intact parathyroid hormone, i.v. Intravenous, ln Natural logarithm, P Phosphorus, TRACP-5b Tartrate-resistant acid phosphatase-5b, VDRA Vitamin D receptor activator
Values are expressed as the median [interquartile range (IQR)] or as frequencies and percentages [n (%)]. *P < 0.05, **P < 0.01
Coefficient [95% CI]
Model 1: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)₂D]
Model 2: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)₂D], Age, Sex
Model 3: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)₂D], Age, Sex, BMI
Model 4: CaSR agonist use (None, Cinacalcet/Evocalcet, Etelcalcetide), VDRA use (None, Alfacalcidol/ Falecalcitriol, Calcitriol, Maxacalcitol), cCa, P, ln [1, 25(OH)₂D], Age, Sex, BMI, Alb

ISSN: 1471-2369